Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Brain ; 129(Pt 11): 3035-41, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17012293

ABSTRACT

Hyperphosphorylated tau protein (P-tau) in CSF is a core biomarker candidate of Alzheimer's disease. Hyperphosphorylation of tau is thought to lead to neurofibrillary changes, a neuropathological hallmark of this type of dementia. Currently, the question is unresolved whether CSF levels of P-tau reflect neurofibrillary changes within the brain of a patient with the illness. Twenty-six patients were included with intra-vitam CSF as well as post-mortem neuropathological data. In the CSF, P-tau phosphorylated at threonine 231 (P-tau231P) was analysed. Post-mortem, scores of neurofibrillary tangles (NFT) and neuritic plaques (NP) were assessed in frontal, temporal, parietal and hippocampal cortical areas. In the same cortical regions, load of hyperphosphorylated tau protein (HP-tau load) was determined. Concentrations of P-tau231P were measured in frontal cortex homogenates. We found significant correlations between CSF P-tau231P concentrations and scores of NFTs and HP-tau load in all neocortical regions studied. The score of NPs was correlated with CSF P-tau231P only within the frontal cortex. There was a correlation between P-tau231P in CSF and brain homogenates. These findings indicate that CSF P-tau231P may serve as an in vivo surrogate biomarker of neurofibrillary pathology in Alzheimer's disease.


Subject(s)
Alzheimer Disease/cerebrospinal fluid , Neocortex/pathology , Neurofibrillary Tangles/pathology , tau Proteins/cerebrospinal fluid , Aged , Aged, 80 and over , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Biomarkers/cerebrospinal fluid , Female , Frontal Lobe/chemistry , Frontal Lobe/pathology , Hippocampus/pathology , Humans , Male , Neocortex/chemistry , Neurofibrillary Tangles/metabolism , Parietal Lobe/pathology , Phosphorylation , Plaque, Amyloid/metabolism , Plaque, Amyloid/pathology , Temporal Lobe/pathology , tau Proteins/analysis
2.
Neurobiol Aging ; 27(1): 10-5, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16298235

ABSTRACT

To study the potential diagnostic value of abnormally phosphorylated tau protein in Creutzfeldt-Jakob disease (CJD) compared to Alzheimer's disease (AD), we determined levels of tau phosphorylated at threonine 231 (p-tau231) and of total tau (t-tau) in cerebrospinal fluid (CSF) of CJD patients, AD patients, and healthy controls (HC). CJD patients showed excessively high t-tau levels but relatively low p-tau(231) concentrations compared to the AD group. t-tau alone yielded the best diagnostic accuracy to differentiate between CJD and AD patients, when compared to p-tau231 and the p-tau231/t-tau ratio (97, 78, and 95% correctly allocated cases, respectively). Our findings indicate a dissociation in the direction of change in CSF levels of t-tau and p-tau231 in CJD when compared to AD.


Subject(s)
Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/diagnosis , Creutzfeldt-Jakob Syndrome/cerebrospinal fluid , Creutzfeldt-Jakob Syndrome/diagnosis , Threonine/metabolism , tau Proteins/cerebrospinal fluid , Age Distribution , Aged , Alzheimer Disease/epidemiology , Biomarkers/cerebrospinal fluid , Creutzfeldt-Jakob Syndrome/epidemiology , Diagnosis, Differential , Female , Germany/epidemiology , Humans , Male , Middle Aged , Phosphorylation , Prevalence , Reproducibility of Results , Sensitivity and Specificity , Sex Distribution , Statistics as Topic
3.
Neurosci Lett ; 391(1-2): 48-50, 2005 Dec 31.
Article in English | MEDLINE | ID: mdl-16165272

ABSTRACT

We investigated the correlation between the apolipoprotein E varepsilon4 allele (apoE epsilon4) carrier status, a major risk factor of Alzheimer's disease (AD), and levels of tau protein phosphorylated at threonine 231 (P-tau(231P)) in cerebrospinal fluid (CSF) in predementia and clinical stages of AD and healthy controls (HC). Thirty-one subjects with mild cognitive impairment (MCI) who had converted to AD during follow-up were included, as well as 71 AD patients, and 29 HC subjects. In MCI, but not in AD and HC, CSF P-tau(231P) levels were significantly higher in apoE epsilon4 carriers compared to non-carriers (p<0.001). Controlling for disease duration, the apoE epsilon4 effect on P-tau(231P) remained significant. Our study indicates that the apoE epsilon4 carrier status should be considered when CSF P-tau(231P) is evaluated as biomarker candidate of AD in MCI subjects.


Subject(s)
Apolipoproteins E/genetics , Cognition Disorders/epidemiology , Cognition Disorders/metabolism , Genetic Carrier Screening/methods , Nerve Tissue Proteins/cerebrospinal fluid , Risk Assessment/methods , Aged , Cognition Disorders/cerebrospinal fluid , Cognition Disorders/genetics , Genetic Predisposition to Disease/epidemiology , Genetic Predisposition to Disease/genetics , Heterozygote , Humans , Male , Prevalence , Risk Factors , Severity of Illness Index , Statistics as Topic , Sweden/epidemiology , United States/epidemiology , tau Proteins
4.
Arch Neurol ; 62(5): 770-3, 2005 May.
Article in English | MEDLINE | ID: mdl-15883264

ABSTRACT

BACKGROUND: The microtubule-associated tau protein abnormally phosphorylated at threonine 231 (p-tau231) has been investigated as a potential marker of Alzheimer disease. Levels of cerebrospinal fluid (CSF) p-tau231 vary across patients with Alzheimer disease. We hypothesized that these variations partially reflect differences in the degree of neuronal damage and therefore may be used to predict structural disease progression. OBJECTIVE: To investigate whether CSF p-tau231 levels correlate with rates of hippocampal atrophy as an in vivo marker of regional neuronal loss. DESIGN AND PATIENTS: We measured hippocampal volumes on the basis of serial magnetic resonance image examinations in 22 patients with Alzheimer disease. In addition, we determined CSF p-tau231 levels at baseline. RESULTS: Levels of CSF p-tau231 were significantly correlated with baseline hippocampal volumes (P<.001) and rates of hippocampal atrophy (left hippocampus, P<.001; right hippocampus, P = .02), independent of disease duration and severity. CONCLUSION: These findings suggest that variations in p-tau231 levels may be used to predict progression of brain atrophy in patients with Alzheimer disease.


Subject(s)
Alzheimer Disease/cerebrospinal fluid , Hippocampus/pathology , Threonine/metabolism , tau Proteins/cerebrospinal fluid , Aged , Alzheimer Disease/complications , Atrophy/etiology , Enzyme-Linked Immunosorbent Assay/methods , Female , Functional Laterality , Humans , Magnetic Resonance Imaging/methods , Male , Mental Status Schedule/statistics & numerical data , Middle Aged , Phosphorylation , Statistics as Topic
5.
Free Radic Biol Med ; 38(6): 746-54, 2005 Mar 15.
Article in English | MEDLINE | ID: mdl-15721985

ABSTRACT

Several recent studies support a link between tau protein phosphorylation and adduction of tau by reactive carbonyls. Indeed, the phosphorylation-dependent adduction of tau by carbonyl products resulting from lipid peroxidation creates the neurofibrillary tangle-related antigen, Alz50. To determine whether epitopes of carbonyl-modified tau are major conformational changes associated with neurofibrillary tangle formation, we examined seven distinct antibodies raised against neurofibrillary tangles that recognize unique epitopes of tau in Alzheimer disease. Consistently, all seven antibodies recognize tau more strongly (4- to 34-fold) after treatment of normal tau with the reactive carbonyl, 4-hydroxy-2-nonenal (HNE), but only when tau is in the phosphorylated state. These findings not only support the idea that oxidative stress is involved in neurofibrillary tangle formation occurring in brains of Alzheimer disease patients, but also show, for the first time, that HNE modifications of tau promote and contribute to the generation of the major conformational properties defining neurofibrillary tangles.


Subject(s)
Alzheimer Disease/immunology , tau Proteins/chemistry , tau Proteins/metabolism , Aged , Aged, 80 and over , Aldehydes/chemistry , Alzheimer Disease/metabolism , Animals , Epitopes/chemistry , Humans , Immunohistochemistry , Lipid Peroxidation , Mice , Models, Genetic , Oxidative Stress , Phosphorylation , Protein Conformation , Time Factors
6.
Arch Gen Psychiatry ; 61(1): 95-102, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14706948

ABSTRACT

BACKGROUND: Abnormal hyperphosphorylation of the microtubule-associated protein tau and its incorporation into neurofibrillary tangles are major hallmarks of the pathogenesis of Alzheimer disease (AD). Different tau phosphoepitopes can be sensitively detected in cerebrospinal fluid (CSF). OBJECTIVE: To compare the diagnostic accuracy of CSF concentrations of tau proteins phosphorylated at 3 pathophysiologically important epitopes (p-tau) to discriminate among patients with AD, nondemented control subjects, and patients with other dementias. DESIGN AND SETTING: Cross-sectional, bicenter, memory clinic-based studies. PARTICIPANTS: One hundred sixty-one patients with a clinical diagnosis of AD, frontotemporal dementia, dementia with Lewy bodies, or vascular dementia and 45 nondemented controls (N = 206). MAIN OUTCOME MEASURES: Levels of tau protein phosphorylated at threonine 231 (p-tau231), threonine 181 (p-tau181), and serine 199 (p-tau199). The CSF p-tau protein levels were measured using 3 different enzyme-linked immunosorbent assays. RESULTS: The mean CSF levels of the studied p-tau proteins were significantly elevated in patients with AD compared with the other groups. Applied as single markers, p-tau231and p-tau181 reached specificity levels greater than 75% between AD and the combined non-AD group when sensitivity was set at 85% or greater. Statistical differences between the assay performances are presented. Particularly, discrimination between AD and dementia with Lewy bodies was maximized using p-tau181at a sensitivity of 94% and a specificity of 64%, and p-tau231 maximized group separation between AD and frontotemporal dementia with a sensitivity of 88% and a specificity of 92%. Combinations of the 3 markers did not add discriminative power compared with the application as single markers. CONCLUSIONS: The p-tau proteins in CSF come closest to fulfilling the criteria of a biological marker of AD. There is a tendency for p-tau proteins to perform differently in the discrimination of primary dementia disorders from AD.


Subject(s)
Alzheimer Disease/diagnosis , Dementia/diagnosis , Organophosphates/cerebrospinal fluid , tau Proteins/cerebrospinal fluid , Aged , Aged, 80 and over , Alzheimer Disease/cerebrospinal fluid , Cross-Sectional Studies , Dementia/cerebrospinal fluid , Dementia, Vascular/cerebrospinal fluid , Dementia, Vascular/diagnosis , Diagnosis, Differential , Enzyme-Linked Immunosorbent Assay , Epitopes/cerebrospinal fluid , Female , Humans , Lewy Body Disease/cerebrospinal fluid , Lewy Body Disease/diagnosis , Male , Middle Aged , Phosphorylation , Predictive Value of Tests , Reference Values
7.
Am J Psychiatry ; 160(2): 376-9, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12562590

ABSTRACT

OBJECTIVE: Differentiation of geriatric major depression from Alzheimer's disease is hampered by overlapping symptoms. Increased CSF concentrations of tau protein phosphorylated at threonine 231 (p-tau(231)) have been suggested as a biomarker for Alzheimer's disease. The authors asked whether p-tau(231) levels improve the differential diagnosis between geriatric major depression and Alzheimer's disease. METHOD: Included were 34 depression subjects, 64 with probable Alzheimer's disease, 17 with possible Alzheimer's disease, and 21 healthy comparison subjects. P-tau(231) concentrations were measured with an enzyme-linked immunosorbent assay. RESULTS: P-tau(231) levels were significantly higher in Alzheimer's disease than in geriatric major depression patients and healthy comparison subjects. For differentiation of probable Alzheimer's disease from major depression, p-tau(231) correctly allocated 87% of subjects. When possible mild Alzheimer's disease was compared to major depression, p-tau(231) correctly allocated 78% of subjects. CONCLUSIONS: CSF p-tau(231) should be evaluated as a potential biological marker for differentiation of geriatric depression from Alzheimer's disease.


Subject(s)
Alzheimer Disease/diagnosis , Depressive Disorder/diagnosis , tau Proteins/cerebrospinal fluid , Aged , Alzheimer Disease/cerebrospinal fluid , Biomarkers/cerebrospinal fluid , Depressive Disorder/cerebrospinal fluid , Diagnosis, Differential , Enzyme-Linked Immunosorbent Assay , Female , Geriatric Assessment , Humans , Male , Phosphorylation , Threonine/metabolism , tau Proteins/metabolism
8.
Arch Neurol ; 59(8): 1267-72, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12164722

ABSTRACT

BACKGROUND: Phosphorylation of tau protein at threonine 231 (using full-length tau, 441 amino acids, for the numbering scheme) (p-tau(231)) occurs specifically in postmortem brain tissue of patients with Alzheimer disease (AD) and can be sensitively detected in cerebrospinal fluid (CSF). OBJECTIVES: To determine to what extent CSF levels of p-tau(231) distinguish patients with AD from control subjects and from patients with other dementias, and to investigate whether p-tau(231) levels are a better diagnostic marker than levels of total tau protein (t-tau) in CSF. DESIGN AND SETTING: Cross-sectional, multicenter, memory clinic-based studies. PARTICIPANTS: One hundred ninety-two patients with a clinical diagnosis of AD, frontotemporal dementia (FTD), vascular dementia, Lewy body dementia, or other neurological disorder and healthy controls. MAIN OUTCOME MEASURES: Levels of CSF tau proteins as measured with enzyme-linked immunosorbent assays. RESULTS: Mean CSF levels of p-tau(231) were significantly elevated in the AD group compared with all other groups. Levels of p-tau(231) did not correlate with dementia severity in AD, and discriminated with a sensitivity of 90.2% and a specificity of 80.0% between AD and all non-AD disorders. Moreover, p-tau(231) levels improved diagnostic accuracy compared with t-tau levels when patients with AD were compared with healthy controls (P =.03) and demented subjects (P<.001), particularly those with FTD (P<.001), but not those with vascular and Lewy body dementias. Sensitivity levels between AD and FTD were raised by p-tau(231) compared with t-tau levels from 57.7% to 90.2% at a specificity level of 92.3% for both markers. CONCLUSION: Increased levels of CSF p-tau(231) may be a useful, clinically applicable biological marker for the differential diagnosis of AD, particularly for distinguishing AD from FTD.


Subject(s)
Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/diagnosis , tau Proteins/cerebrospinal fluid , Adult , Aged , Aged, 80 and over , Biomarkers , Cross-Sectional Studies , Dementia/cerebrospinal fluid , Dementia/diagnosis , Diagnosis, Differential , Female , Humans , Male , Mental Status Schedule , Middle Aged , Phosphorylation , Sensitivity and Specificity , Threonine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...